FIGURE 4. JQ1 treatment repressed innate-type 2 inflammation.

(A)10⁵ ILC2 were transferred into Rag2^−/− Il2rg^−/− mice. Cell recovery efficiency was examined by flow cytometry analysis 2 days after adoptive transfer. (B) 10⁵ ILC2 were transferred into Rag2^−/− Il2rg^−/− mice that were challenged with Alternaria or PBS control, and treated with JQ1 or vehicle control. Number of eosinophils in bronchoalveolar lavage (BAL) was examined by flow cytometry analysis. (C) Airway resistance measured by FlexiVent analysis. (D) Rag1^−/− mice were challenged with Alternaria extracts and treated with JQ1 daily for 3 days. Cytokine production of lung ILC2 was examined one day after the last challenge (i.e. 3 days after the first challenge). (E) Mean fluorescence intensity (MFI) of IL-5 and IL-13 in lung ILC2 of Rag1^−/− mice. (F) Mucous production was examined by PAS staining one day after the last challenge. (G) Percentage of PAS⁺ cells per bronchi. (H) Representative flow cytometry profile of BAL cells in Rag1^−/− mice challenged with Alternaria or PBS control, and treated with JQ1 or vehicle control. (J) Numbers of BAL eosinophils in Rag1^−/− mice challenged with Alternaria or PBS control, and treated with JQ1 or vehicle control. Data are from 4 mice per group, pooled from two independent experiments (A-I) *P < 0.05, **P < 0.01.